Eisai Inc. and Valeant Pharmaceuticals International Inc. Feb. 21 announced that Valeant has acquired the U.S. rights for Targretin (bexarotene) capsules and Targretin (bexarotene) gel 1 percent from Eisai for $65 million, plus potential contingent payments based on milestones.
Targretin capsules are used to treat skin problems arising from a disease called cutaneous T-cell lymphoma (CTCL) when at least one systemic therapy has not worked. The gel version also is used to treat skin problems arising from CTCL when other therapies have not worked or were not tolerated.
As part of the transaction, which takes effect immediately, Eisai has transferred ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.